All News

Findings from the phase 3 KEYNOTE-564 trial support adjuvant pembrolizumab following nephrectomy as a standard-of-care treatment for patients with clear cell renal cell carcinoma.

The improvements occur regardless of PD-L1 status among patients receiving lenvatinib plus pembrolizumab for advanced renal cell carcinoma in the phase 3 CLEAR study.

Using a laser ablation system, imaging mass cytometry is designed to measure over 40 metal isotopes in a tumor sample to identify how immune cells in clear cell renal cell carcinoma are organized.

Factors including measurable residual disease and CAR T-cell expansion appear to predict duration of response following JCAR014 in those with relapsed or refractory chronic lymphocytic leukemia in a phase 1/2 trial.

Results from the phase 1/2 NP30179 trial led the European Commission to grant conditional marketing authorization to patients with relapsed/refractory diffuse large B-cell lymphoma.

Findings from the phase 1b KRYSTAL-1 trial support the continued development of adagrasib in the treatment of patients with KRAS G12C–mutated non–small cell lung cancer and central nervous system metastases.

Docetaxel does not appear to yield meaningful absolute improvements in survival among patients with metastatic castration-sensitive prostate cancer with low-volume, metachronous disease.

The supplemental new drug application for zanubrutinib and obinutuzumab in patients with relapsed/refractory follicular lymphoma is supported by data from the phase 2 ROSEWOOD trial.

Findings from a retrospective review suggest that stereotactic radiosurgery alone may be an effective option vs whole brain radiation therapy among those with small cell lung cancer with brain metastases.

Epcoritamab is a treatment option for patients with relapsed/refractory diffuse large B-cell lymphoma that was approved by the FDA based on findings from the phase 1/2 EPCORE NHL-1 trial.

Data from the phase 2 ROCKstar trial support the approval of belumosudil as a treatment for patients with chronic graft-versus-host-disease in Scotland.

Combining enfortumab vedotin with pembrolizumab yields a manageable safety profile in patients with locally advanced or metastatic urothelial cancer in the phase 1b/2 EV-103 study.

Findings from the phase 3 FRESCO-2 trial support fruquintinib plus best supportive care as a global treatment option for patients with refractory metastatic colorectal cancer.

Patients with select hematologic cancers, including lymphoma and multiple myeloma, appear to benefit from a ready-to-dilute formation of intravenous cyclophosphamide, the new drug application for which was approved by the FDA.

Patients with mantle cell lymphoma who undergo a shorter diagnosis to treatment interval also have worse clinical and disease characteristics on average than those with a longer interval.

Data from the phase 2 MANIFEST study suggest that pelabresib plus ruxolitinib may improve the standard of care for patients with myelofibrosis who are naïve to treatment with JAK inhibitors.

The benefit of nivolumab/ipilimumab plus single-agent nivolumab for unresectable advanced melanoma with poor prognostic characteristics was comparable in all-comers and patients with brain metastases.

Treatment with tepotinib and gefitinib appears to be beneficial compared with chemotherapy in a MET-amplified subgroup of patients with non–small cell lung cancer.

Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.

The FDA fast track designation for paxalisib and radiotherapy for PI3K-mutant solid tumor brain metastases is supported by data from a phase 1 study.

Pembrolizumab plus chemotherapy may improve clinical outcomes over placebo among patients with advanced or recurrent endometrial cancer.

Hypersensitivity reactions following platinum-based treatment appear to be more severe than hypersensitivity reactions after taxanes among patients with cancer.

Overall survival is expected to continue improving among patients with glioblastoma being treated with frontline olaptesed pegol plus radiotherapy and bevacizumab who remain on the phase 1/2 GLORA study.

Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.

Use of an ixabepilone-based companion diagnostic may identify patients with metastatic breast cancer who may benefit from ixabepilone monotherapy.

The FDA sets a Prescription Drug User Fee Act date of January 12, 2024 for the biologics license application for zolbetuximab in the management of Claudin 18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

The safety profile of durvalumab plus tremelimumab among those with unresectable hepatocellular carcinoma in the phase 3 HIMALAYA trial was comparable with the known profiles of each individual agent.

In addition to potentially moving mirvetuximab into earlier lines of treatment for those with platinum-sensitive ovarian cancer, Ritu Salani, MD, also discusses combining the agent with carboplatin to decrease toxicities and improve quality of life.

Datopotamab deruxtecan produces no new safety signals among patients with locally advanced or metastatic non–small cell lung cancer in the phase 3 TROPION-Lung01 trial.

Data from the phase 1/2 eNRGy trial assessing zenocutuzumab in patients with NRG1 fusion–positive cancer support the FDA’s breakthrough therapy designation for the agent as a treatment for pancreatic cancer.